300485.SHE Beijing Science Sun Pharmaceutical Co Ltd
- Market cap
- CNY 3.73B
- P/E
- -
- P/B
- 1.15x
- ROE
- -5.4%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300485.SHE undervalued?
Graham numberThe Graham number of Beijing Science Sun Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Science Sun Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Beijing Science Sun Pharmaceutical Co Ltd yet.
Beijing Science Sun Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Science Sun Pharmaceutical Co Ltd
Beijing Science Sun Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of injections in China. The company offers products for cardiovascular, cerebrovascular, immunomodulation, and nervous systems, and other drugs. It is also involved in raw materials, solid oral preparations, and health products; extraction of traditional Chinese medicine; manufacture of Chinese and Western medicine preparations; research, deve…
Full company profileBeijing Science Sun Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Science Sun Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 616M | 750M | 1.43B | 1.19B | 1.09B | 1.05B | 735M | 477M | 416M | 405M | 350M |
| Gross Profit | 413M | 574M | 1.23B | 1.01B | 916M | 869M | 563M | 336M | 273M | 264M | 231M |
| Operating Income | 299M | 332M | 331M | 177M | 180M | 439M | 255M | 122M | -83.0M | -8.87M | -11.6M |
| EBITDA | 320M | 351M | 355M | 199M | 217M | 495M | 302M | 171M | -36.7M | 60.1M | -207M |
| Net Income | 258M | 282M | 283M | 149M | 155M | 402M | 205M | 103M | -68.9M | 14.6M | -173M |
| EPS | 0.54 | 0.59 | 0.59 | 0.31 | 0.32 | 0.84 | 0.43 | 0.21 | -0.14 | 0.03 | -0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 2.22B | 2.45B | 2.76B | 2.81B | 2.99B | 3.40B | 3.57B | 3.62B | 3.55B | 3.57B | 3.39B |
| Total Liabilities | 119M | 134M | 205M | 94.3M | 141M | 119M | 157M | 155M | 166M | 176M | 143M |
| Shareholders' Equity | 2.10B | 2.32B | 2.55B | 2.67B | 2.80B | 3.24B | 3.37B | 3.44B | 3.36B | 3.37B | 3.23B |
| Cash & Short-term Investments | 1.04B | 1.47B | 573M | 1.28B | 1.18B | 1.30B | 1.12B | 1.17B | 1.57B | 88.1M | 73.6M |
| Total Debt | - | - | 28.2M | 16.9M | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 213M | 108M | 147M | 173M | 264M | 183M | 110M | 21.2M | 136M | 27.1M | - |
| Capital Expenditure | 147M | 141M | 198M | 111M | 118M | 45.9M | 43.3M | 52.9M | 101M | 100M | 47.4M |
| Free Cash Flow | 65.9M | -33.0M | -51.5M | 61.1M | 146M | 137M | 67.1M | -31.7M | 34.8M | -73.2M | -19.8M |
| Ratios | |||||||||||
| ROE | 12.3% | 12.1% | 11.1% | 5.6% | 5.5% | 12.4% | 6.1% | 3.0% | -2.1% | 0.4% | -5.4% |
| ROA | 11.7% | 11.5% | 10.3% | 5.3% | 5.2% | 11.8% | 5.7% | 2.8% | -1.9% | 0.4% | -5.1% |
| Net Profit Margin | 41.9% | 37.5% | 19.8% | 12.5% | 14.2% | 38.3% | 27.9% | 21.6% | -16.5% | 3.6% | -49.3% |
| Debt to Equity | - | - | 0.01x | 0.01x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Science Sun Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.01%
- Forward dividend
- 0.03 CNY
- Payout ratio
- 1.7%
- Ex-dividend date
- May 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 251K | 0.00 | 1.7% |
| 2024 | CNY 10.6M | 0.02 | - |
| 2023 | CNY 41.4M | 0.08 | 40.2% |
| 2022 | CNY 80.9M | 0.17 | 39.5% |
| 2021 | CNY 31.3M | 0.07 | 7.8% |
| 2020 | CNY 30.0M | 0.06 | 19.4% |
| 2019 | CNY 58.1M | 0.12 | 39.1% |
| 2018 | CNY 57.6M | 0.12 | 20.3% |
| 2017 | CNY 60.0M | 0.13 | 21.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 29, 2018.
Who owns Beijing Science Sun Pharmaceutical Co Ltd
- Insiders 57.61%
- Institutions 0.61%
- Public & others 41.78%
- Shares outstanding 482M
- Free float 211M
Beijing Science Sun Pharmaceutical Co Ltd company profile
- Company name
- Beijing Science Sun Pharmaceutical Co Ltd
- Ticker
- 300485.SHE
- ISIN
- CNE100002110
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 489
- Fiscal year end
- December
- Address
- No.8, Xingsheng Street, Beijing, China, 100176
- Phone
- 86 10 6787 7178
- Website
- ssyy.com.cn
About Beijing Science Sun Pharmaceutical Co Ltd
Beijing Science Sun Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of injections in China. The company offers products for cardiovascular, cerebrovascular, immunomodulation, and nervous systems, and other drugs. It is also involved in raw materials, solid oral preparations, and health products; extraction of traditional Chinese medicine; manufacture of Chinese and Western medicine preparations; research, development, production, and sales of tablets, hard capsules, powders, granules, and active pharmaceutical ingredients; outward investment, technology introduction and exchange, international business development, livestock and poultry production, and research and development of bio-organic fertilizers and bio-feeds. In addition, the company is engaged venture capital; equity investment through private equity funds; technology development, transfer, and services for biological products, pharmaceuticals, diagnostic reagents, and medical devices; biotechnology information consulting; sales of immunoassay reagents and laboratory instruments; research, development and industrialization of human vaccines; investment management and consulting for non-securities businesses, as well as inspection and testing services, consulting services, and health food production. The company was founded in 1999 and is headquartered in Beijing, China.
Beijing Science Sun Pharmaceutical Co Ltd management
6- Mr. Biao MaChairman & GM · born 1964
- Ms. Dongna LiangFinancial Director · born 1981
- Mr. Shen YinfuMarketing Director · born 1965
- Ms. Li MaDeputy GM & Director · born 1969
- Mr. Shuangquan KongChief Engineer · born 1974
- Mr. Xue Feng WangDeputy GM, Secretary of the Board & Director · born 1978